Phase II, randomized double blind clinical trial assessing VS 002 in infectious diarrhea
Latest Information Update: 02 Dec 2021
At a glance
- Drugs VS-002 (Primary)
- Indications Diarrhoea
- Focus Therapeutic Use
- Sponsors Nuvara Therapeutics
- 02 Dec 2021 New trial record
- 16 Nov 2021 According to Nuvara Therapeutics media release, one hundredth patient enrolled in this trial at the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR-B); The first data readout is expected in June 2022, and the final readout is expected in March 2023.